Get started
Author

S G Goodman

Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial
2026 · N Pagidipati, M Weber, et al. · European Heart Journal · 1
PDF
Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial
2026 · G G Schwartz, M Szarek, et al. · European Heart Journal
PDF
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
2026 · M J G Leening, D Atar, et al. · European Heart Journal
PDF
Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial
2026 · P Steg, M S Szarek, et al. · European Heart Journal
PDF
Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?
2026 · M Szarek, P G Steg, et al. · European Heart Journal
PDF
Works count: 5
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type